Everolimus in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Neoplasm: A Single-Center Retrospective Study in China

#1454

Introduction: Everolimus showed antitumor activity in patients with advanced pancreatic neuroendocrine tumors in a phase III clinical trial, but data in Chinese patients was limited.

Aim(s): To determine the safety and efficacy of everolimus in Chinese patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).

Materials and methods: A total of 15 patients who were treated with everolimus between November 2013 and December 2015 were evaluated for adverse events and tumor responses retrospectively.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Chen J

Authors: Zhang Y, Chen L, Chen M, Chen J,

Keywords: gastroenteropancreatic neuroendocrine neoplasm,everolimus, treatment,

To read the full abstract, please log into your ENETS Member account.